Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, presented “Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer” during the 29th Annual International Prostate Cancer Update on January 25, 2019 in Beaver Creek, Colorado.

How to cite: Andriole, Jr., Gerald L. “Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer” January 25, 2019. Accessed Feb 2026. https://fluciclovine-18f-pet-ct-impact-on-clinical-management-of-recurrent-prostate-cancer/

Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

Gerald L. Andriole, MD, FACS, asserts that the fluciclovine PET-CT scan has a significant impact on the management of patients with biochemically recurrent prostate cancer.

Summary:

Gerald L. Andriole, MD, FACS, asserts that the fluciclovine PET-CT scan has a significant impact on the management of patients with biochemically recurrent prostate cancer. Prostate cancer recurs in up to 40% of patients treated with surgery or radiation therapy for presumed localized disease. Unfortunately, conventional imaging is unlikely to identify the site of recurrence until the Prostate Specific Antigen (PSA) level exceeds 20 mg/mL. Choline PET scans are an improvement over conventional imaging but are not recommended until the PSA level exceeds 20 mg/mL.

Fluciclovine PET scans identify recurrence disease in about 40% of patients with PSA levels less than 0.8 mg/mL, but identifies higher portions of patients as PSA levels rise. In a treatment impact trial of more than 200 men with biochemically recurrent prostate cancer (the LOCATE study), treatment was changed in 59% of patients once the results of the fluciclovine PET scan were known. In 78% of these cases, the treatment changes were considered to be major.

ABOUT THE AUTHOR

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, is the Chief Medical Officer of Prostatype Genomics AB in St. Louis, Missouri. Dr. Andriole is an internationally recognized key opinion leader in urology with a significant focus on prostate cancer. His research and clinical experience, much of which focuses on genomic testing, allows him to continue to positively impact the quality of care and outcomes for patients diagnosed with prostate cancer.

About The Author

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, is the Chief Medical Officer of Prostatype Genomics AB in St. Louis, Missouri. Dr. Andriole is an internationally recognized key opinion leader in urology with a significant focus on prostate cancer. His research and clinical experience, much of which focuses on genomic testing, allows him to continue to positively impact the quality of care and outcomes for patients diagnosed with prostate cancer. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester in New York. Dr. Andriole then completed his residency in Urology at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. Dr. Andriole went on to complete a fellowship in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 40 years of consistent contributions in the areas of prostate cancer screening and prevention research as well as benign prostatic hyperplasia. He has contributed over 450 peer-reviewed publications. He chaired the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, the Steering Committee of the international REDUCE (reduction by dutasteride of prostate cancer events) Chemoprevention Trial, and the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium. He is a member of numerous societies and associations, including the American Urological Association, the Academy of Master Surgical Educators of the American College of Surgeons, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons. His work has been recognized with a number of awards, including the Outstanding Achievement Award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University, the Alumni Award from Jefferson Medical College, and the Williams Award for Prostate Cancer Research Excellence from the American Urological Association’s Urology Care Foundation.

Share This

Chat with usLiveChat